F16.99 Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder

Name of the Condition

• Hallucinogen Use, Unspecified with Unspecified Hallucinogen-Induced Disorder
• Medical Term: ICD-10-CM F16.99

Summary

Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder refers to the use of hallucinogenic substances associated with an induced disorder, where the specific pattern of use and the nature of the disorder are not detailed. This code is applied when clinical documentation confirms hallucinogen exposure and an associated disorder, but does not specify the type of disorder (e.g., psychosis, mood disorder) or the pattern of use (e.g., abuse, dependence). It is used for cases where an induced disorder is present without further classification.

Causes

Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder typically involves substances that alter perception, mood, or cognitive function, such as LSD, psilocybin, or mescaline. The induced disorder arises from hallucinogen use, but the documentation does not specify the exact nature of the disorder or the pattern of use beyond the association. Psychological or physiological effects of the substance may contribute to the development of the disorder.

Risk Factors

• Recreational or experimental use of hallucinogens
• Pre-existing mental health conditions
• Genetic predisposition to substance use disorders
• Social or peer pressure to use drugs
• Access to hallucinogenic substances

Symptoms

• Altered sensory perceptions (e.g., visual or auditory hallucinations)
• Distorted sense of reality or time
• Mood changes, including euphoria or anxiety
• Impaired judgment or cognitive function
• Possible psychotic symptoms (e.g., delusions, paranoia)
• Behavioral changes consistent with an induced disorder

Diagnosis

Diagnosis requires clinical documentation of hallucinogen use and an associated disorder, with unspecified details. Healthcare providers assess symptoms, substance use history, and ruling out other causes. Laboratory tests or imaging may be used to exclude other conditions, but the diagnosis relies on clinical correlation. The unspecified nature of the disorder and use pattern means specific criteria for a more detailed code are not met.

Treatment Options

Treatment focuses on managing symptoms and addressing the underlying substance use. Interventions may include pharmacotherapy for acute symptoms (e.g., antipsychotics for psychosis), psychotherapy (e.g., cognitive-behavioral therapy), and support for substance use cessation. Referral to addiction specialists or mental health services may be necessary, depending on the severity of the disorder and use.

Prognosis and Follow-Up

Prognosis varies based on the nature of the induced disorder and the pattern of use. With appropriate treatment, symptoms may resolve, but recurrence is possible with continued use. Follow-up care is essential to monitor for relapse, manage chronic symptoms, and address co-occurring conditions. Long-term outcomes depend on sustained abstinence and adherence to treatment.

Complications

• Worsening of induced disorder with repeated use
• Development of chronic mental health conditions
• Social or occupational impairment
• Increased risk of accidents or injuries due to impaired judgment
• Potential for substance use escalation or dependence

Lifestyle & Prevention

• Avoiding hallucinogenic substances to prevent recurrence
• Engaging in stress-reduction techniques (e.g., mindfulness, exercise)
• Building a support network (e.g., family, support groups)
• Educating oneself about the risks of hallucinogen use
• Seeking early intervention for substance use concerns

When to Seek Professional Help

Seek professional help if experiencing persistent or worsening symptoms of an induced disorder, difficulty controlling substance use, or if hallucinogen use is impacting daily functioning. Immediate care is needed for severe symptoms (e.g., suicidal thoughts, severe psychosis) or if use is associated with harm to self or others.

Tips for Medical Coders

When coding F16.99, ensure clinical documentation confirms both hallucinogen use and an induced disorder without specifying the type of disorder or use pattern. Verify that the documentation does not meet criteria for a more specific code (e.g., intoxication, withdrawal, or a named disorder like psychosis). Code assignment relies on the unspecified nature of both the use and the induced disorder as documented.